Value investor Bill Nygren explains why Nvidia isn’t the best AI stock to own now
Read more at MarketWatch
Topics
-
Why Nvidia’s stock looks good to these analysts despite earnings jitters
Even if Nvidia doesn’t deliver a huge revenue beat, some analysts say the stock still looks cheap.MarketWatch - 19h -
U.S. stocks are near record highs. Why are investors so worried?
Sentiment gauges have soured — but the S&P 500 was at record highs just a few days ago. What’s going on?MarketWatch - 2d -
Warren Buffett amasses more cash and sells more stock, but doesn’t explain why in annual letter
The mystery over Warren Buffett’s surprisingly defensive stance deepened over the weekend.NBC News - 4d -
Warren Buffett amasses more cash and sells more stock, but doesn't explain why in annual letter
"The great majority of your money remains in equities," Buffett wrote in his highly-anticipated annual letter. "That preference won't change."CNBC - 4d -
Why MicroStrategy’s stock chart now looks so bearish
The bitcoin play has fallen below a key support zone to trade at the lowest prices seen since before President Trump’s election win.MarketWatch - 19h -
Stock investors stopped freaking out over interest rates. Now this threat is re-emerging.
Investors appear to be doing a lot less hand-wringing over higher interest rates lately, but plenty of market risks are still coming up on the horizon.MarketWatch - 2d -
There are dot-com echoes beyond tech. This Costco shareholder explains why returns will be paltry at best.
A fund manager says there are parallels between now and the 1998-to-2000 period, and not just in the megacap tech stocksMarketWatch - 1d -
An Effective Treatment for Opioid Addiction Exists. Why Isn’t It Used More?
A drug called buprenorphine may be the best tool doctors have to fight the fentanyl crisis. Why hasn’t it been more widely adopted?The New York Times - Feb. 19 -
No, Even the Best Wi-Fi Extender Isn’t Worth Your Time (2025)
We spent hours testing Wi-Fi extenders, but they failed to impress. There are better ways to improve your internet coverage.Wired - 1d
More from MarketWatch
-
Can Nvidia earnings rally the stock market and stop the bleeding in tech?
Highflying “Magnificent Seven” tech stock are in correction territory. Investors are watching Nvidia’s results to assess tech exposure.MarketWatch - 16m -
Taser maker Axon brushes off DOGE budget-cut worries as stock rallies
The company is playing up up its prospects for international growth and its cloud-services businessMarketWatch - 21m -
Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites
Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.MarketWatch - 24m -
T.J. Maxx parent sees broad sales grow, as demand from all income groups rose
Full-year outlook was below current expectations, as it assumes a ‘small negative impact’ from China tariffs.MarketWatch - 28m -
Lumen’s stock got little love from Wall Street analysts. That’s now changing.
Lumen’s stock is rising after a bullish upgrade at Citi. Analysts have hesitated to recommend the telecommunications shares.MarketWatch - 42m
More in Business
-
Can Nvidia earnings rally the stock market and stop the bleeding in tech?
Highflying “Magnificent Seven” tech stock are in correction territory. Investors are watching Nvidia’s results to assess tech exposure.MarketWatch - 16m -
Nvidia reports fourth-quarter earnings after the bell
Nvidia's earnings report on Wednesday will put the finishing touches on one of the most remarkable years from a large company ever.CNBC - 17m -
AppLovin shares tumble 13% as short sellers question its centerpiece AXON ad software
Short seller Fuzzy Panda alleged that the AXON model was "the nexus of a House of Cards" built on fraudulent advertising tactics.CNBC - 18m -
Taser maker Axon brushes off DOGE budget-cut worries as stock rallies
The company is playing up up its prospects for international growth and its cloud-services businessMarketWatch - 21m -
Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites
Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.MarketWatch - 24m